Back to Crohns Disease And Colitis
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01287897

NCT01287897
Completed Phase 2 🇦🇺 Australian site

Who may be able to join

Here is the eligibility information in plain English:

Who might be able to join this trial:

  • You have tried anti-TNF medications (a type of treatment for inflammatory conditions) but they did not work for you, or you were unable to tolerate them
  • Your blood test shows a certain level of inflammation in your body (a marker called hsCRP of 5.0 mg/L or higher)
  • A camera examination of your bowel (colonoscopy) done within 8 weeks before joining the study has shown open sores (ulcers) in your digestive tract, scored using a specific rating system called SES-CD

Who may not be able to join:

  • Women who are pregnant or currently breastfeeding
  • People with Crohn's Disease who have active tunnels or pockets of infection forming between body tissues (fistulae or abscesses)
  • People who have had inflammation of small pouches in the bowel wall (diverticulitis), or who have uncomfortable symptoms related to those pouches
  • People whose blood tests at the start of the study show abnormal results in blood counts or other chemical measurements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
1 February 2011
Est. completion
1 September 2014

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇪 Ireland 🇮🇱 Israel 🇮🇹 Italy 🇳🇿 New Zealand 🇷🇴 Romania 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

8 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg; The CDAI-70 Response Rate at Week 8 in Participants Who Received Placebo and PF-04236921 200 mg; The CDAI-70 Response Rate at Week 12 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg; The CDAI-70 Response Rate at Week 12 in Participants Who Received Placebo and PF-04236921 200 mg

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov